Novel therapies for advanced skin carcinomas.
basal cell carcinoma
immunotherapy
melanoma
squamous cell carcinoma
targeted therapy
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
01
03
2019
accepted:
02
04
2019
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
ppublish
Résumé
Advanced skin carcinomas are a serious therapeutic problem. The statistical analysis shows a continuous increase in the incidence of both melanoma and non-melanoma skin cancers. Traditional therapies are characterized by low effectiveness and patients overall survival is not affected by them. By understanding the molecular pathways that lead to the neoplastic transformation and thanks to the knowledge of the immune system, it is possible to use personalized medicine in novel therapies for advanced skin carcinomas.
Identifiants
pubmed: 33240003
doi: 10.5114/ada.2020.100479
pii: 42289
pmc: PMC7675086
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
660-670Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Br J Dermatol. 2007 May;156 Suppl 3:1-7
pubmed: 17488399
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Cell Mol Life Sci. 2013 Nov;70(21):4055-65
pubmed: 23532409
Cancer Sci. 2012 Dec;103(12):2120-6
pubmed: 22974223
Arch Dermatol Res. 2013 Nov;305(9):845-50
pubmed: 23604961
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Lancet Oncol. 2017 Apr;18(4):435-445
pubmed: 28284557
Lancet Oncol. 2015 Jun;16(6):729-36
pubmed: 25981813
JAMA Dermatol. 2016 Apr;152(4):452-6
pubmed: 26765315
J Am Acad Dermatol. 2014 Jan;70(1):60-9
pubmed: 24189279
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Acta Derm Venereol. 2016 Jan;96(1):3-16
pubmed: 26084328
JAMA Dermatol. 2016 Jul 1;152(7):816-24
pubmed: 27096888
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20
pubmed: 12077575
Cancer Treat Rev. 2015 Sep;41(8):660-70
pubmed: 26096079
Mol Cancer Ther. 2017 May;16(5):861-870
pubmed: 28265006
Mol Cancer Ther. 2010 Aug;9(8):2399-410
pubmed: 20663930
N Engl J Med. 2012 Jun 7;366(23):2171-9
pubmed: 22670903
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Dermatol Surg. 2016 Jan;42 Suppl 1:S49-56
pubmed: 26730974
J Clin Oncol. 2008 Nov 10;26(32):5275-83
pubmed: 18838703
Cancer Discov. 2016 Jul;6(7):703-13
pubmed: 27107038
Clin Cancer Res. 2016 Mar 15;22(6):1325-9
pubmed: 26546616
Curr Treat Options Oncol. 2014 Jun;15(2):302-20
pubmed: 24643778
Oncotarget. 2016 Jul 13;9(15):12408-12417
pubmed: 29552321
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Pathol Res Pract. 2011 Jun 15;207(6):337-42
pubmed: 21531084
Yale J Biol Med. 2015 Jun 01;88(2):167-79
pubmed: 26029015
Future Oncol. 2014 May;10(6):927-36
pubmed: 24941979
Curr Opin Oncol. 2016 Mar;28(2):180-4
pubmed: 26780190
Melanoma Res. 2015 Dec;25(6):461-9
pubmed: 26426764
Cancer. 2018 May 15;124(10):2169-2173
pubmed: 29579331
Clin Cancer Res. 2012 Mar 1;18(5):1435-46
pubmed: 22261807
J Clin Oncol. 2011 Sep 1;29(25):3419-26
pubmed: 21810686
N Engl J Med. 2003 Apr 24;348(17):1681-91
pubmed: 12711744
Cancer Treat Rev. 2014 May;40(4):567-77
pubmed: 24216225
J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5
pubmed: 27067394
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1275-81
pubmed: 23182701
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
J Clin Oncol. 2003 May 15;21(10):1980-7
pubmed: 12743152
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384